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The 2011 Montagna Symposium,
"Advances in Science and Medicine Cata-
lyzed by Pioneering Skin Research,"
was the 60th Anniversary Meeting.*
More than 120 scientists, clinicians, resi-
dents, students, and representatives from
industry and the National Institutes of
Health (NIH) attended. The three-
day program included six sessions: (1)
‘‘Seminal Discoveries in Cancer Biology:
DNA Repair,’’ (2) ‘‘Seminal Discoveries
in Cancer Biology: Hedgehog Signaling,’’
(3) ‘‘Seminal Discoveries in Cancer Biol-
ogy: Signal Transduction and Cancer
Pathogenesis,’’ (4) ‘‘Keratins as Determi-
nant of Health and Disease,’’ (5) ‘‘Iden-
tity, Characterization, and Application
of Skin Stem Cells,’’ and (6) ‘‘Trans-
plantation, Immunosuppression, and Tol-
erance.’’ The sessions were organized
around the goal of this 60th Anniver-
sary Meeting: to showcase the important
research and medical breakthroughs that
were first discovered in skin.
In addition to the invited speakers,
several people were selected to give
short talks based on abstract submis-
sions. As in the previous years, the
discussion after each talk was produc-
tive and lively.
To open the symposium, the Program
Chair, Stuart Yuspa (National Cancer
Institute, NIH, Bethesda, MD), gave an
introduction, that included pictures from
the 1970s, in which he described his
first meeting with William Montagna,
the initiator of this long-running sympo-
sium. Margaret Kripke (University of
Texas MD Anderson Cancer Center,
Houston, TX) followed with the Keynote
Talk, in which she presented a timeline
denoting the origin and highlights of
photoimmunology as a discipline. She
pointed out that the skin is an immuno-
logic organ that reacts to UV radiation
by altering antigen-presenting cells to
stimulate cytokine production. As skin
cells maintain an intimate relationship
with immunologic cells, superficial skin
treatments can have profound systemic
consequences.
Stuart Yuspa started the first day of the
meeting with a historical overview of
the milestones in cancer research and
discoveries regarding the skin. He began
with the description of occupational
skin cancer in chimney sweeps in the
1770s. The next finding did not occur
until the early 1900s, when coal tar and
UV were discovered to cause skin can-
cer. Experiments using synthetic carci-
nogens conducted in the 1940s–1960s
led to several discoveries, including
the role of DNA repair, the ras onco-
gene, and the p53 tumor-suppressor
gene in skin cancer, culminating with
the development of new therapies in
the 2000s.
The goal of the first session, entitled
‘‘Seminal Discoveries in Cancer Biol-
ogy: DNA Repair,’’ was to describe
the role of DNA repair defects in skin
cancer. Kenneth Kraemer (National
Cancer Institute, NIH, Bethesda, MD)
provided a historical overview of xero-
derma pigmentosum, including Kaposi’s
first clinical description in 1874 of the
skin abnormalities, which is still rele-
vant today. He discussed how the cause
of xeroderma pigmentosum was deter-
mined in 1968 to be a DNA excision
repair defect. More recently he disco-
vered that primary melanomas from
xeroderma pigmentosum patients had
UV-type mutations in the PTEN tumor
suppressor gene. DNA extracted from
metastatic melanoma tissue blocks
obtained in the autopsy of a xeroderma
pigmentosum patient in 1971 had multi-
ple PTEN mutations. He advised every-
one to never discard tissue samples as
they might be useful in the future. Laura
Niedernhofer (University of Pittsburgh,
Pittsburgh, PA) discussed why correct
DNA repair is so critical to preventing
cancer (hyperproliferation), neurologic
degeneration, and premature aging (loss
of regenerative capacity). Every day,
cells accumulate many DNA lesions,
including oxidative damage, per day,
which must be repaired. If the damaged
DNA is not repaired and is replicated,
the cells may become cancerous. Un-
repaired DNA damage may lead to
increased cell death or abnormal trans-
cription, resulting in premature aging.
Qingyi Wei (University of Texas MD
Anderson Cancer Center, Houston, TX)
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explained his molecular epidemiologi-
cal studies of the role of polymorphisms
in DNA repair genes in cancer risk in
different populations. He measured
DNA repair capacity using a host-cell
reactivation assay of DNA repair that
can be performed on cultured blood
samples from large numbers of subjects.
He found that the DNA repair pheno-
type and genotype can contribute to
cancer susceptibility in the general popu-
lation. Amanda McCullough (Oregon
Health & Science University, Portland,
OR) ended the session by discussing
new strategies for cancer prevention
involving the use of liposomal and TAT
systems to introduce viral and bacterio-
phage DNA repair enzymes (pyrimidine
dimer-specific DNA glycosylates) into
living cells to increase their DNA repair
capacity.
Andrzej Dlugosz (University of
Michigan, Ann Arbor, MI) began the
second session, ‘‘Seminal Discoveries
in Cancer Biology: Hedgehog Signal-
ing,’’ with an overview of Hedgehog
signaling via the receptor Patched, the
signaling effector Smoothened, and
the Gli family of transcription factors.
In normal tissues, signaling activity is
reversible and is dependent on the
presence of Hedgehog ligand. However,
in basal cell carcinoma (BCC), the
Hedgehog pathway is constitutively
active due to mutations in Patched or
Smoothened, resulting in high levels of
Gli transcriptional activity. On the basis
of studies using several mouse models
targeting GLI2* at different cell popula-
tions in the skin, the development of
BCC subtypes and BCC-like tumors is
defined by the cell of origin, the stage
of the hair growth cycle, and the level
of Hedgehog pathway activity. Anthony
Oro (Stanford University, Palo Alto,
CA) continued the discussion of the
Hedgehog pathway by describing the
structure of the primary cilium, an orga-
nelle found in most cell types that has a
central role in coordinating Hedgehog
pathway components to activate Gli
proteins. MIM (missing in metastasis) is
localized to the basal body, where it
regulates the formation of cilia and
Hedgehog responses. Protein kinase C
iota/lambda (aPKC) and other proteins
colocalize and form a complex with
MIM at the basal body. aPKC inhibition
reduces Sonic Hedgehog signaling
and proliferation of the BCC cell line
in vitro and BCC growth in mice, thus
implicating aPKC as a potential new
target for BCC treatment. Silvia Buona-
mici (Novartis Institutes for Biomedical
Research, Cambridge, MA) described
preclinical and clinical trial data using
the Smoothened inhibitor LDE225,
which showed efficacy in patients
against both BCC and the Hedgehog-
driven brain tumor, medulloblastoma,
although disease progression was noted
later on. Resistance in mouse models
was linked to mutations in Smoothened,
amplification of GLI2, or upregulation of
phosphoinositide 3-kinase (PI3K) signal-
ing. Use of a Smoothened antagonist
and PI3K inhibitor delays the develop-
ment of resistance, arguing for the use of
combination therapy in future trials.
Ervin Epstein (Children’s Hospital
Oakland Research Institute, Oakland,
CA) described a Gorlin syndrome BCC
treatment using a different Hedgehog
inhibitor, GDC-0449. This chemopre-
vention trial showed almost complete
suppression of new tumor development
in patients treated with the drug and
remarkable regression of preexisting
tumors. In contrast to earlier BCC trials
in patients with advanced or metastatic
tumors where drug resistance deve-
loped, resistance was not apparent in
this trial. However, in patients who stop
taking the drug, BCCs begin to grow
again, suggesting that dormant tumor
cells may persist despite a sizeable
reduction in tumor mass. Studies defin-
ing the role of Hedgehog signaling in
BCC development and maintenance
may have far-reaching implications in
oncology, as multiple internal cancers
are also linked to deregulated Hedgehog
signaling.
The first speaker in the third session,
‘‘Seminal Discoveries in Cancer Biol-
ogy: Signal Transduction and Cancer
Pathogenesis,’’ was Stuart Yuspa, who
discussed the effects of IL-1a signaling
on the ras oncogene. Autocrine loops
involving IL-1a, CXCR2 ligands, and
NF-kB signaling result in oncogene-
driven inflammation and angiogenesis.
This theme was continued by Mitchell
Denning (Loyola University School of
Medicine, Maywood, IL), who discussed
the activation of protein kinase C d as
a requirement to initiate the G2/M
cell cycle checkpoint and suppress
tumor formation. Sarah-Jane Cozzi
(LEO Pharma, Inc., Newstead, Queens-
land, Australia) described the ingenol
mebutate field treatment for UVB-
damaged skin and how it removes p53
mutant patches and reduces squamous
cell carcinoma (SCC) formation.
Next were four short talks chosen
from submitted abstracts. Frank de
Gruijl (Leiden University Medical
Center, Leiden, The Netherlands) explai-
ned that UV overexposure depletes p53
patches because it ablates the epider-
mal basal cell layer and thus resets the
carcinoma timeline. Wendy Weinberg
(Center for Drug Evaluation and
Research, FDA, Bethesda, MD) reported
that overexpression of Dp63a increa-
ses expression of the c-Rel subunit of
NF-kB. Blocking this restores calcium
growth arrest. Using an inducible K15-
cre system and triple-crossed SMAD
knockout and activated ras mice, Ruth
White (Oregon Health & Science
University, Portland, OR), a Farber
Award winner, showed that micro-
RNA-9 regulates cell migration and
invasion in SCC. Christine Ho (Univer-
sity of California Berkeley, Oakland,
CA), another Farber awardee, used
statistical methods to determine the
order of mutations in the induction of
cancer. This may provide insights into
cancer treatment and prevention.
The next morning, Pierre Coulombe
(Johns Hopkins University School of
Medicine, Baltimore, MD) opened the
fourth session, ‘‘Keratins as Determinant
of Health and Disease,’’ with a timeline
of publications, beginning in 1953
with James Watson and Francis Crick.
Seminal papers by Werner Franke and
Peter Steinert were published in the
1970s. The number of papers on keratin
research spiked in the 1980s with the
discovery of associated proteins, the
sequences of K5 and K14, and their
use as cassettes for expression. This led
to the discovery that mutations in K5
and K14 caused epidermolysis bullosa
simplex (EBS). Dr Coulombe continued
with the new finding that K5 and K14
form a basket around the nucleus,
which regulates its shape. Angela
Christiano (Columbia University, New
York, NY) described her work in using
Yuspa et al.
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genomics to find new disease genes
associated with hair defects. Next fol-
lowed two short talks chosen from
submitted abstracts: Maria Morasso
(National Institute of Arthritis and
Musculoskeletal and Skin Diseases,
NIH, Bethesda, MD) explained that it
is not clear which signal comes first
in skin development, loss of the peri-
derm, or formation of the epidermal
barrier. Richard Wang (University of
Texas Southwestern Medical Center,
Dallas, TX), a Farber Award winner,
explained how loss of K10 results in
autophagy and that this is mediated
via akt and beclin-1 phosphorylation.
Thomas Magin (Translational Centre
for Regenerative Medicine, Leipzig,
Germany) tied together keratins, the
barrier, and immunity in skin by show-
ing that loss of K1 mediates IL-8 secre-
tion, which affects the integrity of the
cornified envelope. He ended by posing
the question do K1 mutations predispose
patients to inflammatory disorders?
Sancy Leachman (University of
Utah, Salt Lake City, UT) described
the beneficial results of a new treat-
ment for pachyonychia congenital in
which a small interfering RNA that
targets the K6a mutation is injected
into the calluses of patients. Kathleen
Green (Northwestern University Medi-
cal School, Chicago, IL) explained that
cell–cell adhesion molecules were more
than mere glue. Desmogleins are found
everywhere in the cell and regulate
differentiation without their adhesion
domains.
Two short talks chosen from the
submitted abstracts followed. Holger
Schluter (Peter MacCallum Cancer
Center, Melbourne, Australia) showed
that the WNT inhibitory factor WIF-1
regulates epidermal cell differentia-
tion by inducing G1 arrest. Arup Indra
(Oregon State University, Corvallis,
OR) discussed the requirement for
CTIP2 (COUP-TF-interacting protein 2)
to maintain Notch1 levels in basal cells
in order to regulate early differentiation.
Tom Misteli (National Cancer Institute,
NIH, Bethesda, MD) ended this session
with a general description of the nuclear
intermediate filaments, the lamins, and
how a point mutation causes progeria,
a rare genetic condition that causes
rapid aging in children. Currently the
treatment is anti-formyl transferase
drugs, but they work for only a short
time. He is presently working on a small
molecule to target the causal lamin
mutation.
Fiona Watt (Cancer Research UK
London Research Institute, London,
UK) began the fifth session, ‘‘Identity,
Characterization, and Application of
Skin Stem Cells’’ with a history of epi-
dermal stem cells and noted that the
important question of whether the stem
cell is hard wired or a response to
external stimuli remains unanswered.
She discussed the WNT pathway and
how cross-talk between stem cells
and mesenchymal cells results in hair
follicle formation and maintenance. She
reported that as few as 3% of the viable
dermal papilla cells are sufficient to
form a hair follicle. Yann Barrandon
(Ecole Polytechnique Federale de
Lausanne, Switzerland) continued with
a discussion of stem cells’ micro-
environment and stated that it is still
unknown whether tissue stem cells have
memory or whether their fate is deter-
mined by their microenvironment.
Two short talks chosen from the
abstracts followed. Ying Xiao (National
Cancer Institute, NIH, Bethesda, MD)
claimed to have found vessels asso-
ciated with label-retaining cells, sug-
gesting a perivascular reservoir of stem
cells. Krysztof Kobielak (University of
Southern California, Los Angeles, CA)
described the integration of the BMP
and WNT signaling pathways in forming
hair follicles. Dennis Roop (University
of Colorado, Aurora, CO) described
his work using induced pluripotent
stem cells to correct the genetic defect
in EBS. Jakob Tolar (University of
Minnesota, Minneapolis, MN) followed
by describing his success of using
bone marrow stem cells to increase
collagen type VII and laminin 5 produc-
tion in patients with recessive dystro-
phic epidermolysis bullosa (EB) and
junctional EB, respectively. He posed
two unanswered questions: Which
bone marrow cells home to the skin?
Which skin niche do they go to? Yosef
Refaeli (University of Colorado, Aurora,
CO) described his method of using
TAT-myc transfection to produce a
bone marrow stem cell line that
can be transplanted across allogeneic
barriers without producing graft-versus-
host disease.
Next were two short talks chosen
from the submitted abstracts. First, Petra
Boukamp (German Cancer Research
Center, Heidelberg, Germany) discussed
how overexpression of SMAD 7 induces
differentiation rather than quiescence
in stem cells. Second, Ian Mackenzie
(Queen Mary, University of London,
UK) explained how SCC cancer stem
cells can switch back and forth from
nonmotile epithelial cells to motile
mesenchymal cells and that switching
drug treatments is thus necessary in
order to have an impact on all SCC
cells. Michele De Luca (University of
Modena and Reggio Emilia, Modena,
Italy) ended this session with an exciting
description of how using only 3000
limbal stem cells (3% of the total popu-
lation) mixed with stromal cells is suffi-
cient to permanently regenerate the
corneal epithelium in patients who have
suffered chemical burns or infections.
Moreover, this requires only 1 mm of
limbus from an unaffected eye. Thus, he
is currently restoring the sight of patients
who have lost over 95% of their limbal
tissue.
The last session, ‘‘Transplantation,
Immunosuppression, and Tolerance,’’
was chaired by Stephen Katz (National
Institute of Arthritis and Musculoskeletal
and Skin Diseases, NIH, Bethesda, MD),
who gave an overview of adaptive
immunity, including the fact that skin
is the most difficult tissue to adoptively
transplant as an allograft. Kathryn
Wood (University of Oxford, Oxford,
UK) presented a proof of concept that
it is regulatory T lymphocytes that con-
trol or prevent human skin allograft
rejection.
Two short talks chosen from the
submitted abstracts followed. Richard
Presland (University of Washington,
Seattle, WA) described the use of pro-
teomics in saliva samples to detect
potential graft-versus-host disease. Jane
Yoo (University of Washington, Seattle,
WA) explained that 10% of the T lym-
phocytes in the skin are regulatory
T cells, and that the early activation of
these cells modulates local IL-2 signaling,
making the skin more contact sensitive.
Stephen Katz followed with a description
of a mouse model in which self-peptides
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are used to block the autoreactivity of
cytolytic T cells, resulting in mice that
develop systemic tolerance. He also dis-
cussed the experience with and future
prospects of using self-peptides to induce
tolerance in humans. Sarah Arron
(University of California, San Francisco,
CA) found that, even with the use of
several advanced molecular biological
methodologies, there was no evidence
that human papilloma virus is frequently
present in SCCs. This contradicts popular
belief. Shay Soker (Wake Forest Univer-
sity, Winston-Salem, NC) described new
methods using the extracellular matrix on
scaffolds to bioengineer whole organs
from patients’ cells for transplant.
Allan Balmain (University of California,
San Francisco, CA) ended the session
with a keynote talk about the future. He
discussed how to build a genetic network
from a small piece of skin using compu-
tation to find the correlations of genes
with the same scheme to make a com-
plete network. Thus, in the near future,
we will be able to answer specific ques-
tions about specific genes in normal
tissues or in diseases.
2011 SID Eugene M. Farber Travel
Awards for Young Investigators
As in the past, nine young investigators
attended the Montagna Symposium
thanks to a generous donation from the
Eugene M. Farber family through the
Society for Investigative Dermatology.
Janina Baer, PhD
Candidate, Developmental Biology
Department, University of Leipzig
Christine Ho, PhD
Candidate, Department of Statistics,
University of California, Berkeley
Rajan Kulkarni, MD/PhD
Resident, Department of Dermatology,
University of California, Los Angeles
Marco Leung, PhD
Candidate, Graduate School of Biomedical
Sciences, Department of Immunology,
University of Texas MD Anderson Center
Anjali Mishra, MD/PhD
Postdoctoral Researcher, Hematology
and Oncology, The Ohio State
University
Heuijoon Park, PhD
Postdoctoral Fellow, Laboratory of Stem
Cells and Cancer, The Hormel Institute,
University of Minnesota
Padmakumar Velayuthan Chellammal,
PhD
Research Fellow, Laboratory of Cancer
Biology and Genetics, National Cancer
Institute, NIH
Richard Wang, MD/PhD
Instructor, Department of Dermatology,
University of Texas Southwestern Medical
Center
Ruth White, PhD, MD
Candidate, Oregon Health & Science
University School of Medicine
Director’s Award
(additional funds from Mrs Ruth Farber
in memory of Dr Eugene Farber)
LaTondra Lawrence, PhD
Candidate, Texas Women’s University
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*The 2011 Montagna Symposium, ‘‘Advances in
Science and Medicine Catalyzed by Pioneering
Skin Research,’’ was held in Stevenson, Washing-
ton, USA, 13–17 October 2011. Information about
content and support of past symposia and the next
Montagna Symposium on the Biology of Skin can
be found at http://www.montagnasymposium.org.
Montagna 2012
‘‘Keeping It All Together: Adhesion, the Cytoskeleton, and
Signaling in Morphogenesis and Tissue Function’’
11–15 October 2012, Salishan Resort, Gleneden Beach, Oregon
Program Chairs:
Kathleen J. Green, PhD
Departments of Pathology and Dermatology and the R.H. Lurie Cancer Center,
Northwestern University Feinberg School of Medicine, Chicago, Illinois
Masayuki Amagai, MD/PhD
Department of Dermatology, Keio University, Tokyo, Japan
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